V Square Quantitative Management LLC Purchases 1,462 Shares of Bristol-Myers Squibb (NYSE:BMY)

V Square Quantitative Management LLC grew its holdings in shares of Bristol-Myers Squibb (NYSE:BMY) by 3.4% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 45,094 shares of the biopharmaceutical company’s stock after buying an additional 1,462 shares during the quarter. V Square Quantitative Management LLC’s holdings in Bristol-Myers Squibb were worth $2,551,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. AMF Tjanstepension AB grew its stake in Bristol-Myers Squibb by 6.9% in the 3rd quarter. AMF Tjanstepension AB now owns 610,181 shares of the biopharmaceutical company’s stock worth $31,618,000 after acquiring an additional 39,419 shares in the last quarter. Exchange Traded Concepts LLC grew its stake in Bristol-Myers Squibb by 18.1% in the third quarter. Exchange Traded Concepts LLC now owns 26,468 shares of the biopharmaceutical company’s stock worth $1,369,000 after purchasing an additional 4,064 shares in the last quarter. Swedbank AB grew its position in shares of Bristol-Myers Squibb by 0.9% during the 3rd quarter. Swedbank AB now owns 3,139,552 shares of the biopharmaceutical company’s stock worth $162,440,000 after buying an additional 28,427 shares in the last quarter. SeaCrest Wealth Management LLC grew its position in shares of Bristol-Myers Squibb by 35.7% during the 3rd quarter. SeaCrest Wealth Management LLC now owns 21,174 shares of the biopharmaceutical company’s stock worth $1,096,000 after buying an additional 5,576 shares in the last quarter. Finally, Sumitomo Life Insurance Co. grew its position in shares of Bristol-Myers Squibb by 2.8% during the 3rd quarter. Sumitomo Life Insurance Co. now owns 22,850 shares of the biopharmaceutical company’s stock worth $1,182,000 after buying an additional 614 shares in the last quarter. Institutional investors own 76.41% of the company’s stock.

Bristol-Myers Squibb Trading Down 0.4 %

BMY stock opened at $55.93 on Friday. The business’s 50-day moving average is $57.38 and its 200 day moving average is $54.02. Bristol-Myers Squibb has a 12-month low of $39.35 and a 12-month high of $61.10. The stock has a market cap of $113.44 billion, a price-to-earnings ratio of -12.65, a PEG ratio of 2.13 and a beta of 0.45. The company has a current ratio of 1.24, a quick ratio of 1.09 and a debt-to-equity ratio of 2.83.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, February 6th. The biopharmaceutical company reported $1.67 earnings per share for the quarter, topping analysts’ consensus estimates of $1.47 by $0.20. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.81%. On average, sell-side analysts anticipate that Bristol-Myers Squibb will post 6.75 EPS for the current fiscal year.

Bristol-Myers Squibb Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, February 3rd. Stockholders of record on Friday, January 3rd were given a dividend of $0.62 per share. This is a boost from Bristol-Myers Squibb’s previous quarterly dividend of $0.60. The ex-dividend date of this dividend was Friday, January 3rd. This represents a $2.48 annualized dividend and a dividend yield of 4.43%. Bristol-Myers Squibb’s payout ratio is presently -56.11%.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on BMY shares. Wells Fargo & Company increased their target price on shares of Bristol-Myers Squibb from $60.00 to $62.00 and gave the stock an “equal weight” rating in a report on Friday, February 7th. Morgan Stanley increased their target price on Bristol-Myers Squibb from $36.00 to $39.00 and gave the company an “underweight” rating in a research report on Tuesday, November 12th. Bank of America reaffirmed a “neutral” rating and set a $63.00 price objective on shares of Bristol-Myers Squibb in a research report on Tuesday, December 10th. Citigroup raised their price target on shares of Bristol-Myers Squibb from $60.00 to $65.00 and gave the company a “neutral” rating in a report on Tuesday, January 28th. Finally, Jefferies Financial Group upgraded shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating and raised their price target for the company from $63.00 to $70.00 in a report on Monday, December 16th. Two equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating, four have issued a buy rating and three have given a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $57.86.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.